Content about Harvard Drug Group

October 31, 2012

Watson sells Rugby OTC business to Harvard Drug Group for $117 million

Watson Pharmaceuticals on Wednesday announced the sale of its Rugby over-the-counter business to the Harvard Drug Group — a distributor and provider of private-label OTCs and generic prescription products under the Major Pharmaceuticals brand — for approximately $117 million.

PARSIPPANY, N.J. — Watson Pharmaceuticals on Wednesday announced the sale of its Rugby over-the-counter business to the Harvard Drug Group — a distributor and provider of private-label OTCs and generic prescription products under the Major Pharmaceuticals brand — for approximately $117 million.

"I am confident that Major, with its leadership position as a marketer of OTC products, will be more strategically positioned to maximize the value of the long-known and respected Rugby name," stated Paul Bisaro, president and CEO of Watson.

October 18, 2011

HDMA names six new directors; ABC's Neu appointed vice chair

The Healthcare Distribution Management Association on Tuesday named six new members to its board of directors.

ARLINGTON, Va. — The Healthcare Distribution Management Association on Tuesday named six new members to its board of directors — Maria Burns, Burlington Drug Co. VP and corporate secretart; Gregory Drew, Value Drug Co. president; Terrance Haas, Harvard Drug Group CEO; David Neu, AmerisourceBergen president; Dale Smith, H. D. Smith chairman and CEO; and Albert Thomas, senior director and general manager of VaxServe, a Sanofi Pasteur company.